MedTrace Logo

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study

NCT04754542 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2024-09-25

Study results available
· View outcomes & findings →

Summary

The Main Hypothesis of this extension trial is that among those who have successfully discontinued their DMT as part of the DISCOMS trial (i.e. did not have a new MS relapse or brain MRI lesion) and remain off DMT after DISCOMS are at no greater risk of new or worsened MS disease activity compared to those who successfully continued their DMT as part of DISCOMS and remain on DMT, each assessed at least one year after termination of the primary DISCOMS study.

Conditions

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • National Multiple Sclerosis Society

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • John Corboy, MD · University of Colorado, Denver

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-18
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04754542 on ClinicalTrials.gov